Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
0 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Monte Rosa Therapeutics, Inc.’s names, not what it holds today.
Patents granted
0
by type: not read, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
20
6 of them in 2025
Names they are printed under
1
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name1 counted
Monte Rosa Therapeutics, Inc. its own name
named as the applicant on its applications, in US. 4 more under the same name are not counted (printed in CH)
20 publishedNames not counted (1)
Monte Rosa Therapeutics, Inc.
Most of its patents print CH; this name counts in US. 4 granted and 0 published under it are not counted.
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Aug 14, 2025 | 2025/0257048 | METHODS OF PREPARING AN ISOINDOLINONE DERIVATIVE AND CRYSTAL FORMS THEREOF | Pharmaceuticals | Monte Rosa Therapeutics, Inc. |
| May 29, 2025 | 2025/0171420 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Organic fine chemistry | Monte Rosa Therapeutics, Inc. |
| Apr 10, 2025 | 2025/0115582 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Pharmaceuticals | Monte Rosa Therapeutics, Inc. |
| Apr 10, 2025 | 2025/0115581 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | Pharmaceuticals | Monte Rosa Therapeutics, Inc. |
| Jan 30, 2025 | 2025/0037790 | DEGRON AND NEOSUBSTRATE IDENTIFICATION | Computer technology | Monte Rosa Therapeutics, Inc. |
| Jan 16, 2025 | 2025/0022533 | DEGRON IDENTIFICATION USING NEURAL NETWORKS | Computer technology | Monte Rosa Therapeutics, Inc. |
| Sep 26, 2024 | 2024/0317706 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Organic fine chemistry | Monte Rosa Therapeutics, Inc. |
| Sep 19, 2024 | 2024/0308976 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | Pharmaceuticals | Monte Rosa Therapeutics, Inc. |
| Sep 12, 2024 | 2024/0299559 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Organic fine chemistry | Monte Rosa Therapeutics, Inc. |
| Sep 5, 2024 | 2024/0294495 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Pharmaceuticals | Monte Rosa Therapeutics, Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 8 · Organic fine chemistry 6 · Computer technology 2 · Analysis of biological materials 1 · Biotechnology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.